What the 2026 Stroke Guideline Actually Changes: A Bedside Read
A practical 2026 AHA/ASA stroke guideline summary: thrombolysis, thrombectomy, blood pressure and glucose, with a comparison table and linked clinical tools.
Prepared with AI assistance and checked against the linked sources. The update date records an editorial revision; it does not certify physician review.
The 2026 guideline's biggest changes: tenecteplase joins alteplase as a first-line option, thrombectomy expands to larger cores and basilar occlusion, and aggressive blood-pressure and glucose targets are walked back.
- → Tenecteplase now stands alongside alteplase in the 4.5-hour window, and the extended window (4.5–9 hours and unknown-onset) is supported with advanced imaging.
- → Thrombectomy expands to larger ischemic cores and to basilar occlusion, and mobile stroke units earn a formal place.
- → Two reflexes get walked back — intensive blood-pressure lowering and tight glucose control — and children get their own recommendations for the first time.
2026 stroke guidance at a glance
These are selected guideline updates, not a complete eligibility protocol.1
| Common assumption | 2026 guidance | Explore |
|---|---|---|
| Alteplase is the only standard lytic | Either alteplase or tenecteplase is endorsed within 4.5 hours for eligible patients. | IV thrombolysis |
| Low NIHSS excludes treatment | Disability matters. Eligible patients with disabling deficits may benefit despite a low score. | NIHSS guide |
| Unknown onset always excludes lysis | Selected patients may qualify through advanced-imaging mismatch criteria. | Imaging selection |
| A large core always excludes EVT | Some large-core patients benefit; apply the guideline's selection criteria. | EVT eligibility |
| Lower post-reperfusion BP is always better | Intensive systolic lowering below 140 mmHg is not recommended. | BP reference |
| Tight glucose targets improve recovery | Targeting 80–130 mg/dL does not improve outcomes and increases severe hypoglycemia. | Care checklist |
A stroke guideline update is easy to skim and easy to misread. The headline points get quoted in a lecture, the nuance evaporates, and six months later a resident is confidently doing the thing the guideline actually stopped recommending. The 2026 AHA/ASA guideline for the early management of acute ischemic stroke is worth reading slowly, because several of its changes are less about new tools than about being more honest with the ones we already have.1 Here is the bedside version — what actually changes on your next shift, and why.
Tenecteplase joins the front line
The most practice-shaping line is also the least dramatic: within the 4.5-hour window, either alteplase or tenecteplase is now an endorsed choice.1 For anyone who has watched a code stroke, the appeal of tenecteplase is obvious — a single bolus instead of an hour-long infusion, which is simpler to give and easier to move a patient with. Years of trials showing it holds its own against alteplase have finally accumulated into a guideline that treats them as genuine alternatives rather than treating one as experimental.
The corollary matters just as much. For patients with clearly disabling deficits, the guideline supports rapid thrombolysis regardless of the NIHSS number — a useful corrective to the habit of talking oneself out of treating a low-scoring but genuinely disabling deficit, such as isolated aphasia or a hand that will end a career. Conversely, for genuinely non-disabling deficits, dual antiplatelet therapy is preferred over lytics. ABCD2 pertains to TIA risk, not stroke severity. Stroke and TIA antiplatelet decisions require their respective eligibility and bleeding-risk assessment.
The clock gets a little more forgiving
The rigid 4.5-hour wall softens for selected patients. For stroke of unknown onset — the classic wake-up stroke — or presentations 4.5 to 9 hours out, thrombolysis is supported when advanced imaging shows the right pattern: a diffusion or perfusion mismatch that says salvageable tissue is still on the table.1 This is the guideline catching up to what many comprehensive centers were already doing, and it reframes the question from "what time is it?" to "what does the tissue look like?" For eligibility detail, see IV thrombolysis eligibility and time windows.
Bedside pearl
Extended-window treatment requires both timing and appropriate imaging selection. If your center can get fast MRI or CT perfusion, the wake-up stroke you would once have waved off may now be a treatable one. Know your own door-to-imaging pathway before you need it at 3 a.m.
Thrombectomy keeps expanding
The endovascular envelope widens again. The guideline extends thrombectomy toward patients with larger ischemic cores — the group we used to exclude on the assumption there was too little to save — following the recent large-core trials.1 And basilar artery occlusion, long treated in a haze of uncertainty, now gets a strong recommendation for thrombectomy within 24 hours in patients with an NIHSS of 10 or more. For posterior-circulation strokes, that is a real change in tone: a stronger recommendation within defined eligibility criteria.
Two reflexes to unlearn
The most instructive updates are the ones that tell us to do less. First, blood pressure: intensive systolic lowering to below 140 mmHg is not recommended, even after complete reperfusion. Pushing pressure down hard does not improve functional outcomes after intravenous thrombolysis and may cause harm after thrombectomy.1 The instinct to normalize the number on the monitor is exactly the instinct to resist.
Second, glucose: intensive control to a tight 80–130 mg/dL range is not recommended, because it does not improve outcomes and it buys real hypoglycemia risk.1 Glucose treatment still needs a monitored clinical protocol that avoids hypoglycemia. Both changes share a theme — a decade of trials teaching us that tidy numbers are not the same as better brains.
Children get a guideline of their own
For the first time, the document includes recommendations for pediatric stroke — a population that has spent years borrowing adult protocols by necessity.1 The emphasis is on early recognition (childhood stroke is still routinely missed or delayed) and on the safety and potential benefit of thrombectomy in selected children. It will not change most adult-medicine shifts, but for pediatric emergency and neurology teams it is a landmark: an expansion of this acute ischemic stroke guideline, alongside earlier dedicated pediatric statements.
Care moves upstream
Finally, the systems-of-care story continues its march out of the hospital. Mobile stroke units — ambulances carrying a CT scanner and the ability to start treatment at the curb — earn formal recommendation on the strength of outcome data, and the guideline reinforces expanded access to clot-removal procedures.1 The through-line of the last decade holds: the biggest gains in stroke care keep coming from shortening the distance between symptom and treatment, not just from new drugs. See the broader trends in stroke care behind these changes. For the prevention side — the everyday habits that protect the vessels feeding the brain — see vascular health and brain function.
What to take to your next shift
If you remember three things: tenecteplase is a first-class option and a low NIHSS alone should not exclude an otherwise eligible patient with disabling deficits; extended-window treatment still depends on timing and imaging; and the reflex to crush blood pressure and glucose is the reflex to drop. The same document also made a swallow screen before any oral intake Class 1 — the clinical version of that recommendation is in post-stroke dysphagia. The rest is refinement of a direction stroke care has held for years — treat more people, faster, and stop chasing numbers that never changed outcomes. As always, this is an educational summary; the full guideline is the source of truth, and local protocols and individual judgment still govern the patient in front of you.1
Frequently asked questions.
Is tenecteplase now preferred over alteplase?
The 2026 guideline endorses either alteplase or tenecteplase within the 4.5-hour window rather than declaring one universally preferred. Tenecteplase's single-bolus administration makes it operationally attractive, especially where patients are transferred, but both are supported choices.
What is the extended thrombolysis window?
For selected patients with unknown-onset (wake-up) stroke or presentation 4.5 to 9 hours from onset, thrombolysis is supported when advanced imaging (diffusion-weighted MRI or perfusion imaging) shows a mismatch indicating salvageable tissue. Imaging selection supplements timing and other eligibility criteria; it does not remove them.
Did thrombectomy eligibility change?
Yes. The guideline expands thrombectomy toward patients with larger ischemic cores, reflecting recent large-core trials, and gives a strong recommendation for thrombectomy in basilar artery occlusion within 24 hours when the NIHSS is 10 or higher.
Why walk back blood pressure and glucose targets?
Because the trial evidence did not support them. Intensive systolic BP lowering below 140 mmHg did not improve outcomes and may harm after thrombectomy, and tight glucose control (80–130 mg/dL) did not improve outcomes while increasing hypoglycemia. The guideline reflects treating dangerous extremes rather than chasing tight numbers.
What is new for pediatric stroke?
For the first time the guideline includes recommendations specifically for children, emphasizing early recognition of childhood stroke and the safety and potential benefit of thrombectomy in selected pediatric patients.
What are the biggest changes in the 2026 acute ischemic stroke guideline?
Five things at the bedside: tenecteplase joins alteplase as a first-line thrombolytic; the thrombolysis and thrombectomy windows widen for imaging-selected patients; thrombectomy eligibility keeps expanding toward large-core and other previously excluded groups; the aggressive blood pressure and glucose targets are walked back; and children get dedicated recommendations for the first time. The sections above summarize selected recommendations and link the guideline.
References.
- American Heart Association/American Stroke Association. 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2026. AHA Journals
Related guides
Keep building the picture.
- Thrombectomy eligibility Bedside selection for early, late-window, and large-core EVT.
- ABCD2 score calculator Non-disabling deficits get DAPT, not lytics — ABCD² is the CHANCE/POINT score behind that split.
- Post-stroke dysphagia The same 2026 guideline made a swallow screen before any oral intake Class 1.
- Acute blood pressure targets Pre- and post-reperfusion BP thresholds in one place.
- Trial library The trials behind each of these guideline changes.
Article written by